Introduction {#cam41361-sec-0001}
============

Colorectal cancer (CRC) is the third most common cancer worldwide [1](#cam41361-bib-0001){ref-type="ref"}, [2](#cam41361-bib-0002){ref-type="ref"}, and approximately one‐third of the incidence is accounted for rectal cancer. Preoperative radiotherapy (RT) is used for a part of rectal cancer patients to reduce the risk of local recurrence or to enable surgery for initially nonresectable tumors. It can be given either as short‐course RT or long‐course chemoradiotherapy (CRT) with 5‐fluorouracil (5‐FU) depending on clinical staging. The latter is usually recommended for locally advanced rectal cancer [3](#cam41361-bib-0003){ref-type="ref"}.

However, the response to preoperative therapy in terms of tumor regression or disease outcome is variable, and some patients might benefit from a more individualized risk‐benefit assessment than is currently available [4](#cam41361-bib-0004){ref-type="ref"}, [5](#cam41361-bib-0005){ref-type="ref"}, [6](#cam41361-bib-0006){ref-type="ref"}. Thus far, there are no clinical molecular markers that can aid in predicting response to (C)RT or enable stratifying patients into separate treatment groups according to their prognosis [3](#cam41361-bib-0003){ref-type="ref"}. Therefore, various factors have been investigated in order to determine their predictive or prognostic potential regarding (C)RT. These factors include for example markers associated with cell proliferation, apoptosis, angiogenesis, inflammatory response, diverse oncogenic pathways, epithelial‐mesenchymal transition, microsatellite instability, or the stem‐cell nature of cancer cells [6](#cam41361-bib-0006){ref-type="ref"}, [7](#cam41361-bib-0007){ref-type="ref"}, [8](#cam41361-bib-0008){ref-type="ref"}, [9](#cam41361-bib-0009){ref-type="ref"}, [10](#cam41361-bib-0010){ref-type="ref"}, [11](#cam41361-bib-0011){ref-type="ref"}, [12](#cam41361-bib-0012){ref-type="ref"}, [13](#cam41361-bib-0013){ref-type="ref"}, [14](#cam41361-bib-0014){ref-type="ref"}, [15](#cam41361-bib-0015){ref-type="ref"}, [16](#cam41361-bib-0016){ref-type="ref"}.

CIP2A (cancerous inhibitor of PP2A) inhibits protein phosphatase 2A (PP2A) tumor suppressor activity and thereby promotes malignant cell transformation and tumor growth [17](#cam41361-bib-0017){ref-type="ref"}, [18](#cam41361-bib-0018){ref-type="ref"}, [19](#cam41361-bib-0019){ref-type="ref"}. CIP2A is known to be overexpressed in several cancer types, and its overexpression has been demonstrated to associate with reduced survival for example in gastric cancer [20](#cam41361-bib-0020){ref-type="ref"}, serous ovarian carcinoma [21](#cam41361-bib-0021){ref-type="ref"}, nonsmall‐cell lung carcinoma [22](#cam41361-bib-0022){ref-type="ref"}, chronic myeloid leukemia [23](#cam41361-bib-0023){ref-type="ref"}, CRC [24](#cam41361-bib-0024){ref-type="ref"}, and head and neck squamous cell carcinoma (HNSCC) [25](#cam41361-bib-0025){ref-type="ref"}. CIP2A expression has also been linked to poorly differentiated histology in various cancers [18](#cam41361-bib-0018){ref-type="ref"}, [19](#cam41361-bib-0019){ref-type="ref"}, [26](#cam41361-bib-0026){ref-type="ref"}, [27](#cam41361-bib-0027){ref-type="ref"}. CIP2A promotes several signaling pathways contributing to cell proliferation, apoptosis resistance, and senescence evasion. In addition to Myc, CIP2A‐mediated inhibition of protein phosphatase 2A (PP2A) is known to stimulate Akt kinase and E2F transcription factor 1 (E2F1) pathways [18](#cam41361-bib-0018){ref-type="ref"}, [19](#cam41361-bib-0019){ref-type="ref"}. In normal tissues, except testis, CIP2A is expressed only at a low level, and its inhibition does not impair normal development or viability in mice [19](#cam41361-bib-0019){ref-type="ref"}, [28](#cam41361-bib-0028){ref-type="ref"}.

In connection to irradiation, CIP2A expression has been previously studied in radiated mouse testes and found to be expressed in radioresistant testicular stem‐cell population, where it is targeted by octamer‐binding transcription factor 4 (Oct4). The cooperation of CIP2A and Oct4 was shown to contribute to radioresistance in HNSCC cell lines and tumorigenicity in HNSCC xenograft models [25](#cam41361-bib-0025){ref-type="ref"}. Importantly, the in vivo relevance of CIP2A in mediating intestinal radioresistance was recently demonstrated when CIP2A was shown to physically interact with Myc and support Myc‐mediated intestinal regeneration in response to irradiation in vivo [29](#cam41361-bib-0029){ref-type="ref"}.

In this study, we have examined the relationship between CIP2A expression and radiation response both by immunohistochemistry (IHC) in clinical samples collected from rectal cancer patients and in vitro by assessing the effects of *CIP2A* knockdown on cell survival in a CRC cell line exposed to radiation.

Material and Methods {#cam41361-sec-0002}
====================

Patients and tumor samples {#cam41361-sec-0003}
--------------------------

The study population consisted of 210 rectal cancer patients with tumors located in either middle or distal rectum. They were operated at Turku University Hospital between 2000 and 2009. Representative formalin‐fixed paraffin‐embedded (FFPE) surgical specimens were retrieved from the archives of the Department of Pathology, Turku University Hospital, and full clinicopathologic data were retrospectively gathered from those patients. Superficial tumors operated by local excision were excluded from the study as well as tumors from patients with distant metastases at the time of diagnosis. Pretreatment biopsies from patients treated with preoperative radiotherapy were also collected but not included in the analyses due to the small number of samples (*n *=* *10).

The patients received either short‐course preoperative RT (*n *=* *89, 42%), long‐course preoperative (C)RT (*n *=* *51, 24%), or no treatment before surgery (*n *=* *70, 33%), according to common clinical recommendations [30](#cam41361-bib-0030){ref-type="ref"}. The type of treatment was chosen based on preoperative tumor staging, which included computed tomography (CT) or magnetic resonance imaging (MRI) of the rectum, abdominal CT, and chest X‐ray or CT.

Short‐course RT consisted of a total dose of 25 Gy delivered over 5 days in 5 Gy fractions, and the patients were operated on the following week. Long‐course RT was given in 1.8 Gy fractions to a total dose of 50.4 Gy over 6 weeks with (*n *=* *43) or without (*n *=* *8) chemotherapy, and the patients were operated five to 7 weeks after RT. Chemotherapy included either bolus 5‐fluorouracil (5‐FU, *n *=* *5) or capecitabine (*n *=* *38). The type of surgery was anterior resection among 113 (54%) patients and abdominoperineal resection among 94 patients (45%). Three patients (1%) were operated with low Hartmann\'s procedure or other type of surgery. Lymphovascular invasion was found in 45 of 157 (29%) tumors. Patients with established high‐risk features were treated with adjuvant chemotherapy.

Tumors were staged according to the TNM criteria applicable at the time of surgery [31](#cam41361-bib-0031){ref-type="ref"}. Follow‐up information was available for 206 patients. The median follow‐up time was 74.5 months, and disease recurrence (local or distant) was observed among 67 patients (33%). The basic clinicopathologic characteristics are shown in Table [1](#cam41361-tbl-0001){ref-type="table-wrap"}.

###### 

Patient characteristics (*n *=* *210)

                                                          Short‐course RT, *n* (%)   Long‐course RT, *n* (%)   Control, *n* (%)
  ------------------------------------------------------- -------------------------- ------------------------- ------------------
  Sex                                                                                                          
  Male                                                    55 (45.5)                  33 (27.3)                 33 (27.3)
  Female                                                  34 (38.2)                  18 (20.2)                 37 (41.6)
  Mean age (years)                                        65.3                       64.3                      73.9
  Median age (years)                                      68.0                       66.1                      74.1
  Range                                                   34.3--82.0                 41.9--81.2                47.0--92.3
  Preoperative T[a](#cam41361-note-0003){ref-type="fn"}                                                        
  T1‐2                                                    27 (30.0)                  0 (0)                     21 (30.0)
  T3                                                      54 (60.7)                  2 (3.9)                   12 (17.1)
  T4a                                                     1 (1.1)                    46 (90.2)                 3 (4.3)
  Tx                                                      7 (7.9)                    1 (2.0)                   34 (48.6)
  Postoperative T                                                                                              
  T1                                                      3 (3.4)                    2 (3.9)                   5 (7.1)
  T2                                                      32 (36.0)                  7 (13.7)                  26 (37.1)
  T3                                                      50 (56.2)                  28 (54.9)                 36 (51.4)
  T4[b](#cam41361-note-0004){ref-type="fn"}               3 (3.4)                    13 (25.5)                 3 (4.3)
  T0                                                      1 (1.1)                    1 (2.0)                   0 (0)
  Postoperative N                                                                                              
  N0                                                      52 (58.4)                  32 (62.7)                 39 (55.7)
  N1                                                      25 (28.1)                  14 (27.5)                 16 (22.9)
  N2                                                      12 (13.5)                  5 (9.8)                   12 (17.1)
  Nx                                                      0 (0)                      0 (0)                     3 (4.3)
  Postoperative stage                                                                                          
  Stage I                                                 26 (29.2)                  5 (9.8)                   25 (35.7)
  Stage II                                                26 (29.2)                  27 (52.9)                 17 (24.3)
  Stage III                                               36 (40.4)                  18 (35.3)                 28 (40.0)
  No vital tumor                                          1 (1.1)                    1 (2.0)                   0 (0)
  Postoperative grade                                                                                          
  G1                                                      9 (10.1)                   10 (19.6)                 13 (18.6)
  G2                                                      56 (62.9)                  33 (64.7)                 46 (65.7)
  G3                                                      22 (24.7)                  3 (5.9)                   11 (15.7)
  Gx                                                      2 (2.2)                    5 (9.8)                   0 (0)
  Circumferential margin (mm)                                                                                  
  0                                                       3 (3.4)                    8 (15.7)                  4 (5.7)
  0 ≤ CRM ≤ 2                                             8 (9.0)                    9 (17.6)                  7 (10.0)
  \>2                                                     65 (73.0)                  22 (43.1)                 30 (42.9)
  Unknown                                                 13 (14.6)                  12 (23.5)                 29 (41.4)
  Follow‐up status                                                                                             
  Alive without disease                                   56 (62.9)                  19 (37.3)                 30 (42.9)
  Alive with disease                                      2 (2.2)                    3 (5.9)                   4 (5.7)
  Died of disease                                         19 (21.3)                  20 (39.2)                 20 (28.6)
  Died of other causes                                    12 (13.5)                  9 (17.6)                  16 (22.9)

RT, radiotherapy; CRM, circumferential resection margin.

Missing information for two patients in the long‐course RT group.

Includes T3 tumors with threatened circumferential margin involvement.

John Wiley & Sons, Ltd

The study was conducted in accordance with the Declaration of Helsinki and the Finnish legislation for the use of archived tissue specimens and associated clinical information. The clinical data were retrieved, and the histological samples were collected and analyzed with the endorsement of the National Supervisory Authority for Welfare and Health, Finland (Dnro 1709/32/300/02, May 13, 2002).

Evaluation of the tumor regression grade {#cam41361-sec-0004}
----------------------------------------

Tumor regression after long‐course (C)RT was determined by JS and EK according to a simplified classification based on Dworak and Rödel scales [32](#cam41361-bib-0032){ref-type="ref"}, [33](#cam41361-bib-0033){ref-type="ref"}, [34](#cam41361-bib-0034){ref-type="ref"}, [35](#cam41361-bib-0035){ref-type="ref"}. The response to RT was divided into three categories: poor (only minimal or no tumor regression), moderate (some detectable vital tumor cells or cell groups), or excellent response (very few or no detectable tumor cells).

Immunohistochemistry {#cam41361-sec-0005}
--------------------

The most optimal FFPE tissue samples were selected to obtain enough tumor material for analyses. Antigen retrieval was performed by heating the 5‐μm sections in microwave oven in Target Retrieval buffer, pH 9.0 (Dako Denmark A/S, Glostrup, Denmark) twice for 7 min. The rabbit polyclonal CIP2A antibody [36](#cam41361-bib-0036){ref-type="ref"} was diluted to 1:4000 in Antibody Diluent Buffer (Dako Denmark A/S, Glostrup, Denmark) and incubated for 1 h at RT. For detection, Dual Link System---HRP and DAB Chromogen System (Dako Denmark A/S, Glostrup, Denmark) were used. The stainings were performed with Lab Vision Autostainer.

Analysis of CIP2A expression {#cam41361-sec-0006}
----------------------------

Tumor samples from 204 patients were included in the final analyses. Six tumors could not be reliably evaluated with IHC due to the limited amount of tumor cells. Two observers evaluated the cytoplasmic IHC staining of CIP2A blinded to clinical data (AE all samples and EB 40 samples). Tissue from normal testis was used as a positive control. Cytoplasmic staining was scored as negative (0), weak (1 + ), moderate (2 + ), or strong (3 + ). Strong staining intensity corresponded to the positive control, weak staining intensity was still distinguishable from the background, and moderate staining intensity was intermediate between these two. Representative immunostainings of CIP2A are shown in Figure [1](#cam41361-fig-0001){ref-type="fig"}.

![Different CIP2A immunohistochemical cytoplasmic staining intensities in rectal adenocarcinomas. (A) Negative for CIP2A protein expression. (B) Weak (1 + ) CIP2A protein expression. (C) Moderate (2 + ) CIP2A protein expression. (D) Strong (3 + ) CIP2A protein expression. Original objective magnification 20x.](CAM4-7-698-g001){#cam41361-fig-0001}

For statistical analyses, the most intense cytoplasmic staining index (MICI) and average cytoplasmic staining index (ACI) were used to classify the samples into two subgroups according to the index value being either below or above median level [37](#cam41361-bib-0037){ref-type="ref"}. The indices were calculated with the following formula: I = 0 × f0 + 1 × f1 + 2 × f2 + 3 × f3, where I is the staining index and f0--f3 the fractions of cells (from 0 to 1) showing a defined level of staining (from 0 to 3). To obtain MICI, the area containing the most intense staining of cancer cells was chosen from each sample, and the fraction of cancer cells (percentage/100) belonging to each staining intensity category was estimated from that area. ACI was calculated as an average of three randomly selected areas from which the fraction of cancer cells belonging to each staining intensity category was estimated. Theoretically, the indices could vary between 0 and 3. The samples were observed with 10× objective magnification.

Cell culture experiments and irradiation studies {#cam41361-sec-0007}
------------------------------------------------

The RKO CRC cell line (ATCC^®^ CRL‐2577^™^) was purchased from ATCC (Manassas, VA). Cells were grown in Dulbecco\'s minimal essential medium supplemented with 10% FBS, 2 mmol/L glutamine, and 1% penicillin/streptomycin.

Cells in the logarithmic growth phase were transfected with CIP2A or scrambled double‐stranded small interfering RNAs (siRNA) using Oligofectamine (Invitrogen^™^, Thermo Fisher Scientific, Waltham, MA) according to the manufacturer\'s instructions. The siRNA sequences have been previously published [26](#cam41361-bib-0026){ref-type="ref"}. The cells were lysed in RIPA buffer, and CIP2A protein levels were analyzed by Western blotting with CIP2A antibody (2G10‐3B5; Santa Cruz Biotechnology, Dallas, TX) as described previously [38](#cam41361-bib-0038){ref-type="ref"}. HRP‐conjugated anti‐GAPDH mAb (mAbcam 9484; Abcam, Cambridge, UK) was used as a loading control.

Radiation experiments were performed using the 96‐well clonogenic cell survival assay as previously described [39](#cam41361-bib-0039){ref-type="ref"}. Forty‐eight hours after the siRNA transfections, the cells were harvested into single‐cell suspensions. The cells were irradiated at room temperature in separate Falcon tubes containing 25 000 cells/treatment in 6 mL culture medium (4167 cells/mL). The irradiation was performed at the radiotherapy department using a linear accelerator (Clinac 2100; Varian CA) with 6 MeV photon irradiation at a dose rate of 2 Gy/min.

After irradiation, the cells were further diluted into 50 mL culture medium in appropriate concentration and 200 μL of cell suspension/well was pipetted in duplicate into 96‐well plates. The number of cells per well was adjusted according to the expected cell death as follows: control 2 cells/well, 0.75 Gy 3 cells/well, 1.25 Gy 4 cells/well, 2.5 Gy 8 cells/well, 5 Gy 20 cells/well, and 7.5 Gy 100 cells/well. The plates were incubated in the cell culture incubator until visible colonies were formed. The plates were examined using an inverted phase contrast microscope. Wells containing colonies of at least 32 cells were considered positive.

The surviving fractions (SF) were calculated with the formula: $$\text{SF}\, = \,\frac{\text{no.\ of\ positive\ wells/no.\ of\ plated\ cells\ in\ control}}{\text{no.\ of\ positive\ wells\ in\ control}}$$

The survival curves of cancer cells were fitted using the linear quadratic (LQ) model (SF = exp\[‐(αD + βD^2^)\]); D, radiation dose). The area under the curve (AUC) values were calculated with a numerical integration algorithm. The results were calculated from three experiments for each treatment with duplicate plates for each radiation dose.

Statistical analysis {#cam41361-sec-0008}
--------------------

Statistical analyses were performed with IBM SPSS Statistics for Windows, version 21.0 (IBM Corporation, Armonk, NY). Frequency table data were calculated with the Pearson\'s chi‐squared and Fisher\'s exact tests. 2 × 2 tables were used to calculate odds ratios (OR) and 95% confidence intervals (CI) using the exact method. Interobserver reproducibility of the IHC assessments was tested with weighted kappa, which was calculated with the intraclass correlation coefficient (ICC) test in parallel mode with a two‐way random model using consistency assumption and the average measures option. The interobserver reproducibility was very good for MICI (weighted kappa 0.83, 95% CI: 0.67--0.91) and moderate for ACI (weighted kappa 0.56, 95% CI: 0.16--0.77).

Univariate survival analysis for disease‐free survival (DFS) and disease‐specific survival (DSS) were performed using the Kaplan--Meier method and log‐rank test. DFS was calculated from the date of diagnosis to disease recurrence or death from any cause, and the observations were censored at the date of last follow‐up. DSS was measured from the date of diagnosis to the date of death from rectal cancer, and the observations were censored at death from other causes or the date of last follow‐up. Cox\'s proportional hazards regression model was used for multivariate survival analysis, and covariates were entered in a stepwise backward manner. For the irradiation experiments, calculations were performed with Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA) and paired *t*‐test was used to compare the mean AUC values. All statistical tests were two‐sided, and *P*‐values under 0.05 were considered statistically significant.

Results {#cam41361-sec-0009}
=======

CIP2A expression in relation to clinicopathologic variables {#cam41361-sec-0010}
-----------------------------------------------------------

CIP2A MICI was found to associate with patient age at the time of diagnosis and with the depth of tumor invasion (pT). Low CIP2A MICI (≤median, cut‐off 1.20) was more frequently observed among the younger patients (age ≤ median, cut‐off 70 years; Fisher\'s exact test, *P *=* *0.023; OR 1.98, 95% CI: 1.13--3.47) and among patients with most invasive tumors (pT4 vs. pT1--pT2; Fisher\'s exact test, *P *=* *0.022). No association was found between CIP2A MICI and patient sex, postoperative histological differentiation grade, lymph node status, postoperative stage, circumferential resection margin (CRM, 1 or 2 mm cut‐off), or lymphovascular invasion (yes vs. no). Low CIP2A ACI (≤median, cut‐off 0.94) was observed slightly more often among the well‐differentiated tumors (Fisher\'s exact test, *P *=* *0.050). The relationship of CIP2A MICI with selected clinicopathologic variables is presented in Table [2](#cam41361-tbl-0002){ref-type="table-wrap"} and for CIP2A ACI in Table [S1](#cam41361-sup-0001){ref-type="supplementary-material"}.

###### 

Association of clinicopathologic variables of rectal cancer patients with CIP2A protein expression defined by the most intense cytoplasmic staining index (*n *=* *204)

                                                                           CIP2A most intense cytoplasmic staining index   *P*‐value[a](#cam41361-note-0005){ref-type="fn"}   
  ------------------------------------------------------------------------ ----------------------------------------------- -------------------------------------------------- -------
  Age                                                                                                                                                                         
  ≤70 years                                                                67 (57.8)                                       36 (40.9)                                          0.023
  \>70 years                                                               49 (42.2)                                       52 (59.1)                                          
  Postoperative T[b](#cam41361-note-0006){ref-type="fn"}                                                                                                                      
  pT1‐2                                                                    36 (31.3)                                       37 (42.0)                                          0.022
  pT3                                                                      63 (54.8)                                       48 (54.5)                                          
  pT4                                                                      16 (13.9)                                       3 (3.4)                                            
  Post‐treatment tumor regression[c](#cam41361-note-0007){ref-type="fn"}                                                                                                      
  Poor                                                                     15 (42.9)                                       11 (91.7)                                          0.006
  Moderate/ excellent                                                      20 (57.1)                                       1 (8.3)                                            
  DSS[d](#cam41361-note-0008){ref-type="fn"}                                                                                                                                  
  ≥36 months                                                               95 (90.5)                                       60 (76.9)                                          0.014
  \<36 months                                                              10 (9.5)                                        18 (23.1)                                          

Pearson\'s chi‐squared or Fisher\'s exact test.

Excluding one tumor that could not be assessed for postoperative T.

Assessed only after long‐course (chemo)radiotherapy.

Disease‐specific survival, alive versus death of disease.
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CIP2A expression in relation to tumor regression grade {#cam41361-sec-0011}
------------------------------------------------------

CIP2A MICI in relation to tumor regression was evaluated in 47 samples from patients having received long‐course (C)RT. Among patients who had moderate or excellent response to (C)RT, CIP2A MICI was more frequently below median than in the poorly responding group (Fisher\'s exact test, *P *=* *0.006; OR 14.7, 95% CI: 1.70--126.4). Similarly, low CIP2A ACI was associated with moderate or excellent treatment response (Fisher\'s exact test, *P *=* *0.007; RR 1.63, 95% CI: 1.20--2.20). Tumor regression in relation to CIP2A MICI is presented in Table [2](#cam41361-tbl-0002){ref-type="table-wrap"} and in relation to CIP2A ACI in Table [S1](#cam41361-sup-0001){ref-type="supplementary-material"}.

CIP2A expression in relation to survival {#cam41361-sec-0012}
----------------------------------------

Patients with tumors having CIP2A MICI below median had higher 36‐month disease‐specific survival rate than patients with CIP2A above median when DSS was analyzed as a dichotomous variable (Fisher\'s exact test, *P *=* *0.014; OR 2.85, 95% CI: 1.23--6.59). (Table [2](#cam41361-tbl-0002){ref-type="table-wrap"}). A similar trend was also observed between low CIP2A expression and higher 36‐month DSS rate in the case of CIP2A ACI (Fisher\'s exact test, *P *=* *0.060, Table [S1](#cam41361-sup-0001){ref-type="supplementary-material"}). However, when using 60 months as a cut‐off point, the survival difference between CIP2A MICI levels was no longer significant. No significant relationship was found between CIP2A MICI and DFS as a dichotomous variable using either 36 or 60 months as a cut‐off point.

In the univariate survival analysis, CIP2A MICI was not associated with DFS or DSS. The multivariate analysis for DSS was performed with the following covariates: CIP2A MICI (below vs. above median), RT treatment group (short RT or long (C)RT vs no treatment), sex (female vs. male), age (below vs. above median, 70 years as cut‐off), postoperative nodal status (N1 or N2 vs. N0), the presence of lymphovascular invasion (yes vs. no), CRM (≤2 mm vs. \>2 mm), and disease recurrence status (yes vs. no). The remaining factors predicting reduced DSS were CIP2A MICI above median (*P *=* *0.014, HR 3.02, 95% CI: 1.26--7.26), age above 70 years (*P *=* *0.002, HR 3.98, 95% CI: 1.65--9.59), long‐course (C)RT (*P *=* *0.040, HR 3.19, 95% CI 1.05--9.66), and disease recurrence (*P *\<* *0.0001, HR 291.8, 95% CI: 36.9--2307.1).

The multivariate analysis for DFS was performed with the same variables as DSS excluding disease recurrence status. CIP2A MICI did not remain as an independent predictive factor, whereas age above 70 years (*P *=* *0.026, HR 1.80, 95% CI: 1.07--3.01) and postoperative nodal status N2 were predictive for reduced DFS (*P *=* *0.002, HR 2.88, 95% CI: 1.48--5.62). Results from multivariate analyses are shown in Table [3](#cam41361-tbl-0003){ref-type="table-wrap"}.

###### 

Cox\'s multivariate analysis for disease‐free and disease‐specific survival (*n *=* *138)[a](#cam41361-note-0010){ref-type="fn"}

                                 Number of patients   Disease‐free survival   Disease‐specific survival                                       
  ------------------------------ -------------------- ----------------------- --------------------------- ------------ -------------- ------- --------------
  Age                                                                                                                                         
  ≤70 years (ref)                63                   **0.026**               1.80                        1.07--3.01   **0.002**      3.98    1.65--9.59
  \>70 years                     75                                                                                                           
  Preoperative treatment group                                                                                                                
  Short‐course RT                69                   0.331                   0.73                        0.39--1.37   0.783          1.15    0.42--3.13
  Long‐course (C)RT              31                   0.431                   1.31                        0.67--2.59   **0.040**      3.19    1.05--9.66
  No (C)RT (ref)                 38                                                                                                           
  CIP2A MICI                                                                                                                                  
  ≤Median (ref)                  78                   0.966                   0.99                        0.56--1.73   **0.014**      3.02    1.26--7.26
  \>Median                       60                                                                                                           
  Disease recurrence                                                                                                                          
  Yes                            39                                                                                    **\<0.0001**   291.8   36.9--2307.1
  No (ref)                       99                                                                                                           
  Postoperative N                                                                                                                             
  N1                             35                   0.180                   1.49                        0.83--2.65   0.831          1.11    0.43--2.83
  N2                             19                   **0.002**               2.88                        1.48--5.62   0.945          1.05    0.30--3.60
  N0 (ref)                       84                                                                                                           
  Sex                                                                                                                                         
  Female                         62                   0.200                   0.70                        0.40--1.21   0.473          0.75    0.35--1.63
  Male (ref)                     76                                                                                                           
  Lymphovascular invasion                                                                                                                     
  Yes                            43                   0.071                   1.63                        0.96--2.77   0.666          1.19    0.54--2.62
  No (ref)                       95                                                                                                           
  CRM                                                                                                                                         
  ≤2 mm                          35                   0.230                   1.40                        0.81--2.43   0.297          1.47    0.71--3.02
  \>2 mm (ref)                   103                                                                                                          

CI, confidence interval; CRM, circumferential resection margin; (C)RT, (chemo)radiotherapy; HR, hazard ratio; MICI, most intense cytoplasmic staining index; N, lymph node status; ref, reference.

Complete data for all the covariates were available for 138 patients.

Cox regression test.

*P*‐values \< 0.05 (in bold) are considered statistically significant.

John Wiley & Sons, Ltd

The effect of CIP2A knockdown on radiosensitivity {#cam41361-sec-0013}
-------------------------------------------------

The mean AUC values for *CIP2A* siRNA‐transfected cells and scrambled control were 1.7 ± 0.1 Gy and 2.1 ± 0.1 Gy, respectively. The cells with *CIP2A* knockdown were significantly more sensitive to radiation than the control cells (paired *t*‐test, *P *=* *0.015). The cell survival curves from the irradiation experiments and corresponding Western blot results are presented in Figure [2](#cam41361-fig-0002){ref-type="fig"}.

![(A) The cell survival curves from the irradiation experiments show the mean surviving fraction ±SE for each radiation dose. The RKO cells treated with CIP2A siRNA (black) were more sensitive to radiation (mean AUC 1.7 ± 0.1 Gy) than the control cells treated with scrambled siRNA (gray) (mean AUC 2.1 ± 0.1 Gy; paired t‐test, *P *=* *0.015). (B) The corresponding Western blot demonstrates the reduction in CIP2A protein expression in siRNA‐treated cells (siCIP2A) in comparison with scrambled siRNA‐treated cells (siSCR) and nontreated control cells (contr). GADPH was used as a loading control.](CAM4-7-698-g002){#cam41361-fig-0002}

Discussion {#cam41361-sec-0014}
==========

To our knowledge, the association between CIP2A expression and clinical response to radiotherapy has not been previously studied in rectal cancer. We have investigated CIP2A protein levels in rectal adenocarcinomas from patients receiving either short‐ or long‐course preoperative (chemo)radiotherapy or no treatment before surgery. As the majority of rectal tumors have been shown to overexpress CIP2A [40](#cam41361-bib-0040){ref-type="ref"}, we chose to use the most intense cytoplasmic staining index (MICI) together with the average cytoplasmic staining index (ACI) instead of only a dichotomous positive vs. negative IHC scoring system. In the long‐course (C)RT group, patients with low‐CIP2A‐expressing tumors were more likely to respond to preoperative treatment as compared to those with high‐CIP2A‐expressing tumors. This was supported by the observation that transfection of RKO CRC cells with *CIP2A* siRNA sensitized them to irradiation and decreased their survival.

Our results are in agreement with previous findings demonstrating a role for CIP2A in promoting intestinal progenitor cell resistance to irradiation and other DNA‐damaging therapies [29](#cam41361-bib-0029){ref-type="ref"}. High CIP2A expression has been found to contribute to radioresistance in HNSCC cells [25](#cam41361-bib-0025){ref-type="ref"}, whereas CIP2A immunonegative tumors have been shown to respond favorably to cancer therapies [19](#cam41361-bib-0019){ref-type="ref"}, [21](#cam41361-bib-0021){ref-type="ref"}. Additionally, the depletion of CIP2A transcription by siRNA has been found to significantly increase radiosensitivity in cervical squamous cell carcinoma and hepatocellular carcinoma cell lines [41](#cam41361-bib-0041){ref-type="ref"}.

In this study, low CIP2A expression was found to be more common among the most invasive tumors (pT4) than high CIP2A expression. Still, low CIP2A expression level was associated with better treatment response, defined by tumor regression grade, after long‐course (C)RT. Low CIP2A expression level was also found to be linked with higher 36‐month DSS rate of the patients in categorical analysis. Although CIP2A MICI was not associated with survival in the univariate Kaplan--Meier analysis, low CIP2A expression level was found to remain as an independent prognostic factor for increased DSS together with younger age and nonrecurrent disease, while having received long‐course (C)RT as preoperative therapy was associated with reduced DSS. A prognostic role of CIP2A is also supported by several previous studies, which have found an association between low CIP2A expression and increased survival [27](#cam41361-bib-0027){ref-type="ref"}.

In CRC, studies investigating CIP2A as a prognostic biomarker have yielded variable results. In one study, no significant difference was found in five‐year DSS between patients having tumors with either weak or strong CIP2A immunostaining. The survival difference remained statistically nonsignificant even when tumors of colon and rectum were examined separately [40](#cam41361-bib-0040){ref-type="ref"}. In contrast, high *CIP2A* mRNA levels have been associated with reduced overall survival (OS) among CRC patients [24](#cam41361-bib-0024){ref-type="ref"}. A similar relationship has been observed between strong CIP2A protein expression and reduced OS in *KRAS* wild‐type CRC patients after surgical treatment of liver metastases [42](#cam41361-bib-0042){ref-type="ref"}.

In this study, CIP2A expression levels before and after preoperative treatment could not be compared because an adequate number of representative pretreatment biopsies were not available. At the time of diagnosis, biopsy material was not required for molecular pathology and thus often obtained in too small amounts for further analyses. However, it would be of interest to study whether the initial pretreatment CIP2A expression level or the magnitude of change in CIP2A expression during (C)RT also associates with radiation response. CIP2A expression after irradiation has been studied in vivo in mouse testis where its transcription or expression levels did not significantly change over the 144‐h observation period [25](#cam41361-bib-0025){ref-type="ref"}. This could support the hypothesis that initially low CIP2A expression might result in more pronounced response to preoperative (C)RT. Additionally, our finding that the knockdown of CIP2A expression by siRNA increases the radiosensitivity of CRC cells in vitro implies that there could be a causal connection between the level of CIP2A expression and radiation response. In conclusion, our results suggest that low CIP2A protein expression level is associated with a favorable response to long‐course (C)RT and with increased disease‐specific survival in rectal cancer. This connection between reduced CIP2A expression and radiosensitivity was further demonstrated in cell irradiation experiments. Thus, the validity of CIP2A as a predictive biomarker for preoperative treatment response in rectal cancer warrants further investigation in the pursuit of providing more personalized treatment modalities for rectal cancer patients.
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**Table S1.** Association of clinicopathologic variables of rectal cancer patients with CIP2A protein expression defined by the average cytoplasmic staining index (*n *=* *198).
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Click here for additional data file.
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